Journal of Medical Economics
Volume 26, 2023 - Issue 1
Oncology
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1
Vicente Escudero-Vilaplanaa Hospital Gregorio Marañón, Madrid, Spain
https://orcid.org/0000-0003-4417-8321
https://orcid.org/0000-0003-4417-8321, Roberto Collado-Borrella Hospital Gregorio Marañón, Madrid, Spainhttps://orcid.org/0000-0001-7639-0082
https://orcid.org/0000-0001-7639-0082, , Amelia Insac Hospital Clínico Universitario de Valencia, Valencia, Spainhttps://orcid.org/0000-0002-3438-6170
https://orcid.org/0000-0002-3438-6170, , Elena Fernándeze OSI Bilbao-Basurto, Bilbao, Spainhttps://orcid.org/0000-0003-1624-8206
https://orcid.org/0000-0003-1624-8206, Ivana Sullivanf Hospital de la Santa Creu i Sant Pau, Barcelona, Spainhttps://orcid.org/0000-0002-0434-3436
https://orcid.org/0000-0002-0434-3436, , , David Carcedoh Hygeia Consulting, Madrid, SpainCorrespondence[email protected]
https://orcid.org/0000-0002-2809-7399
https://orcid.org/0000-0002-2809-7399 & Alba Manzanequei Hospital Universitari Mútua Terrassa, Terrassa, Spainhttps://orcid.org/0000-0002-7935-8317
https://orcid.org/0000-0002-7935-8317 show all